Business
SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform
BOSTON and LAUSANNE, Switzerland, April 26, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone
About this update from Sophia Genetics Sa
[{"type":"text","content":"BOSTON and LAUSANNE, Switzerland, April 26, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of the largest knowledge sharing platforms connecting thousands of healthcare professionals and researchers across more than 70 countries.\n\n \n \n\n \nFounded in 2011, SOPHiA GENETICS set out to create a world where every clinician has a multidimensional understanding of diseases by integrating data and sharing insights for the benefit of patients across the globe. What began as a research tool for hospitals and research labs, has since evolved into the SOPHiA DDM™ Platform of today – a collaborative community of thousands of healthcare specialists. Since launch, the platform has grown exponentially, analyzing 39 to 70 percent more patient profiles year-over-year. It took SOPHiA GENETICS five years to hit the milestone of 500,000 genomic profile analyses and just under two years to double that.\nHaving facilitated the analysis of one million genomic profiles, the SOPHiA DDM™ Platform has been exposed to a highly diverse array of genomic variants needed to continually hone machine learning algorithms for the accurate detection of rare and challenging cases. By then sharing these insights, users across the growing SOPHiA DDM™ Community can save time pulling the right signal from the noise to reveal what matters most and help make better-informed decisions for their patients.\nPowered by AI and machine learning, the cloud-based SOPHiA DDM™ Platform was designed to scale, enabling the company to compute more data, support additional data modalities, expand to new geographies, and deploy new applications including added capabilities to longitudinally follow patient's data while being treated for cancer. Since its inception in genomics, the SOPHiA DDM™ Platform has evolved to include the analysis of clinical, biological, genomic, and radiomic data to support the numerous ongoing multimodal studies supported by SOPHiA GENETICS. The company is also collaborating with GE Healthcare to advance cancer care by better targeting and matching treatment to a patient's genomic profile and cancer type.\n\"Since launching our SOPHiA DDM™ platform, it has become clear that our vision to bridge s...